NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

J&J's high expectations for Rybrevant are driven mainly by its August approval with Lazcluze, which outperformed Tagrisso in ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

This summary of recent health news includes U.S. Senator Bernie Sanders advocating for cheaper Ozempic, new findings on ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

Hello Health Rounds Readers! Today we highlight research findings reported at ESMO 2024, the annual meeting of the European ...